TY - CHAP
T1 - Polyclonal and monoclonal antibodies in clinic
AU - Wootla, Bharath
AU - Denic, Aleksandar
AU - Rodriguez, Moses
PY - 2014
Y1 - 2014
N2 - Immunoglobulins (Ig) or antibodies are heavy plasma proteins, with sugar chains added to amino-acid residues by N-linked glycosylation and occasionally by O-linked glycosylation. The versatility of antibodies is demonstrated by the various functions that they mediate such as neutralization, agglutination, fixation with activation of complement and activation of effector cells. Naturally occurring antibodies protect the organism against harmful pathogens, viruses and infections. In addition, almost any organic chemical induces antibody production of antibodies that would bind specifically to the chemical. These antibodies are often produced from multiple B cell clones and referred to as polyclonal antibodies. In recent years, scientists have exploited the highly evolved machinery of the immune system to produce structurally and functionally complex molecules such as antibodies from a single B clone, heralding the era of monoclonal antibodies. Most of the antibodies currently in the clinic, target components of the immune system, are not curative and seek to alleviate symptoms rather than cure disease. Our group used a novel strategy to identify reparative human monoclonal antibodies distinct from conventional antibodies. In this chapter, we discuss the therapeutic relevance of both polyclonal and monoclonal antibodies in clinic.
AB - Immunoglobulins (Ig) or antibodies are heavy plasma proteins, with sugar chains added to amino-acid residues by N-linked glycosylation and occasionally by O-linked glycosylation. The versatility of antibodies is demonstrated by the various functions that they mediate such as neutralization, agglutination, fixation with activation of complement and activation of effector cells. Naturally occurring antibodies protect the organism against harmful pathogens, viruses and infections. In addition, almost any organic chemical induces antibody production of antibodies that would bind specifically to the chemical. These antibodies are often produced from multiple B cell clones and referred to as polyclonal antibodies. In recent years, scientists have exploited the highly evolved machinery of the immune system to produce structurally and functionally complex molecules such as antibodies from a single B clone, heralding the era of monoclonal antibodies. Most of the antibodies currently in the clinic, target components of the immune system, are not curative and seek to alleviate symptoms rather than cure disease. Our group used a novel strategy to identify reparative human monoclonal antibodies distinct from conventional antibodies. In this chapter, we discuss the therapeutic relevance of both polyclonal and monoclonal antibodies in clinic.
KW - Antibody
KW - Disorders
KW - Monoclonal antibodies
KW - Polyclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=84931271058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931271058&partnerID=8YFLogxK
U2 - 10.1007/978-1-62703-586-6_5
DO - 10.1007/978-1-62703-586-6_5
M3 - Chapter
C2 - 24037837
AN - SCOPUS:84931271058
SN - 9781627035859
T3 - Methods in Molecular Biology
SP - 79
EP - 110
BT - Human Monoclonal Antibodies
PB - Humana Press Inc.
ER -